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Abstract
Marine microbial diversity offers enormous potential for discovery of compounds of crucial importance in healthcare, food 
security and bioindustry. However, access to it has been hampered by the difficulty of accessing and growing the organisms 
for study. The discovery and exploitation of marine bioproducts for research and commercial development requires state-
of-the-art technologies and innovative approaches. Technologies and approaches are advancing rapidly and keeping pace is 
expensive and time consuming. There is a pressing need for clear guidance that will allow researchers to operate in a way 
that enables the optimal return on their efforts whilst being fully compliant with the current regulatory framework. One 
major initiative launched to achieve this, has been the advent of European Research Infrastructures. Research Infrastructures 
(RI) and associated centres of excellence currently build harmonized multidisciplinary workflows that support academic and 
private sector users. The European Marine Biological Research Infrastructure Cluster (EMBRIC) has brought together six 
such RIs in a European project to promote the blue bio-economy. The overarching objective is to develop coherent chains 
of high-quality services for access to biological, analytical and data resources providing improvements in the throughput 
and efficiency of workflows for discovery of novel marine products. In order to test the efficiency of this prototype pipeline 
for discovery, 248 rarely-grown organisms were isolated and analysed, some extracts demonstrated interesting biochemical 
properties and are currently undergoing further analysis. EMBRIC has established an overarching and operational structure 
to facilitate the integration of the multidisciplinary value chains of services to access such resources whilst enabling critical 
mass to focus on problem resolution.
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Introduction
The marine environment provides a huge and, as yet, under-
tapped resource for the biotechnology industry (Blasiak 
et al. 2018). However, whilst individual enzymes/products 
or their host organisms have been exploited for commer-
cial products, to date there has not been a concerted effort 
to make use of marine organisms in a more holistic way. 
Indeed, a recent study highlighted the unevenness of com-
mercial activities in this sector, as may be seen from patents 
derived from marine organisms: of almost 13,000 sequences 
of marine origin assigned to patents at the time of writing, 
47% were filed by a single multinational company (see 
Blasiak et al. 2018). Marine science now has a wealth of 
tools to overcome key bottlenecks in access to and releasing 
the potential of marine organisms. It has been estimated that 
less than 1% of novel marine genetic resources will make 
it to the market place (Royal Society 2017). The massive 
growth in opportunities afforded by new high throughput 
technologies enables understanding of the biological and 
chemical make-up of novel compounds and screening for 
them in the first place. This has been aided by a similar 
expansion in computing power and analytical tools in order 
to put such discoveries into context.
The European Marine Biological Research Infrastructure 
Cluster (EMBRIC–https ://www.embri c.eu/) brought six 
European Research Infrastructures together (Brennecke et al. 
2018) and aimed to fulfil one of the key rules for ‘pragmatic 
blue growth’ described in a recent policy paper by being a 
‘well-designed institution’ (Burgess et al. 2018) although 
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marine biotechnology, per se, was notable by its absence in a 
recent study of the management of ocean resources (Klinger 
et al. 2018). The European Strategy Forum for Research 
Infrastructures (ESFRI–https ://ec.europ a.eu/resea rch/infra 
struc tures /index _en.cfm?pg=home) have encouraged the 
establishment of Research infrastructures (RIs): facilities, 
resources and services used by the science community to 
conduct research and foster innovation.
Materials and methods overview
There are numerous routes that may be taken in the discov-
ery process. The first step is to select where to sample, fol-
lowed by the prioritisation of organisms and selective sam-
pling to enrich for organisms with the desired properties. 
Obviously, in order to invest time and effort wisely, these 
choices are critical, because the oceans are vast and their 
potential enormous (Royal Society 2017), but the organisms 
are difficult to isolate and when they are, they are generally 
slow-growing. A typical workflow begins with the source of 
organism, where there are two options:(1) isolation directly 
from the environment; or (2) selection from those already 
isolated; the latter for example, may be taken from ex situ 
biological resource collections such as the microbial domain 
Biological Resource Centres (mBRC—OECD 2007). A 
number of such mBRCs are coordinated either by the Micro-
bial Resource Research Infrastructure (MIRRI; www.mirri 
.org/) or the European Marine Biological Research Centre 
(EMBRC-ERIC) (https ://www.embrc .eu/). MIRRI brings 
together 31 international mBRCs which, together, hold a 
total of > 330 K microorganisms, ranging from bacteria 
(including cyanobacteria) to yeasts, filamentous fungi and 
algae. EMBRC brings together marine biological stations 
and institutes organised through nine national nodes.
At each level of the discovery process there are techni-
cal issues to be addressed. EMBRIC has begun the process 
of mapping current mechanisms available to help facilitate 
how the potential of novel organisms is identified and the 
organisms with the most potential targeted (Brennecke 
et al. 2018). Options to be considered are for example using 
metagenomics to assess sample content; using proteomics 
and metabolomics to identify chemical targets; analysing 
information on chemical interactions (e.g. allelopathic, 
grazer defence metabolites) to identify bioactive com-
pounds; and using metabarcoding technology to characterise 
the species compositions of mass samples of environmen-
tal DNA. Bottlenecks could also revolve around compli-
ance with regulation for example obtaining permissions to 
collect (Kamau et al. 2010; Overmann and Scholz 2017; 
Smith et al. 2017). Despite numerous attempts to explore the 
microbial diversity of the planet, to date the majority has yet 
to be isolated and cultured and consequently has remained 
largely untapped, especially with regard to bioprospecting 
(Overmann and Smith 2017). Up to 95% of marine life (by 
weight) has been estimated to be microbial in nature (Vier-
ros et al. 2016). The failure to recover phylogenetically novel 
microbial lineages of bacteria and fungi can be attributed 
to current isolation methodology that is often found to be 
inadequate (Overmann 2012). Phenotypically novel types of 
bacteria often have unknown growth requirements and, are 
highly fastidious, for example: Myxobacteria, Acidobacte-
ria and Dehalococcoides ethenogenes (Foesel et al. 2013; 
Maymó-Gatell et al. 1997; Sanford et al. 2002). There is 
a need to employ improved methodology and undertake a 
systematic approach to culturing microorganisms such as 
harnessing “culturomics” (Lagier et al. 2012). Dedicated 
isolation protocols are required, e.g. selective media: to date, 
less than ca. 1% of all microorganisms can be cultivated (Pan 
Ming Huang et al. 2012; Overmann et al. 2017). Develop-
ment of novel approaches to eliciting enhanced production—
media development, use of small molecule elicitors, targeted 
heterologous expression and promoter refactoring. Growth/
fermentation technologies need to be expanded, allowing 
bulking up for production (e.g. Hewitt and Nienow 2010). 
Once the organism is grown access to the most appropriate 
methodologies and technologies is needed:
• Immunological ID, Next Generation Sequencing (whole 
sample; e.g. Chun and Rainey 2014);
• Sequencing; genome, proteins; metabolomics (e.g. Nac-
cache et al. 2014);
• Population/environmental metagenomics (e.g. Lorenz 
and Eck 2005);
• Bioinformatic tools, data interoperability; Common tools 
and software (e.g. Okonechnikov et al. 2012);
• Identification of bioactive compounds (e.g. Kim and 
Mendis 2006).
  In identifying and isolating promising metabolites loss 
of resources and time by rediscovery of already known 
compounds must be avoided by using optimal de-repli-
cation protocols (e.g. Dias et al. 2012). Supporting tech-
nologies are:
• Genome mining of biosynthetic potential (e.g. Wagner-
Döbler et al. 2002);
• Bioassay technologies (e.g. Delamarche et al. 2005);
• Routes from crude extract assay hits to scaling, identi-
fying, purifying and structural characterising bioactive 
compounds (e.g. Li and Vederas 2009) utilising, where 
possible, genome guided characterisation in complement 
with spectroscopic guided characterisation.
Improved routes from novel bioactive organisms and 
bioactive extracts, identifying and purifying key bioac-
tives as either a single compound or a synergistic mixture 
of compounds is needed. In response to this issue EMBRIC 
World Journal of Microbiology and Biotechnology (2019) 35:107 107 Page 2 of 8
 1 3
is facilitating the search by exploring ways to integrate and 
mine metabolomic/genomic/metagenomic data. There is also 
a critical need to bridge the gap between ‘feature identifica-
tion’ and compound chemical characterisation. Data analysis 
tools to integrate genome reading with metabolite informa-
tion are seen as a crucial success factor. Thus, an essential 
first step is combining parallel, complementary streams to 
speed discovery (see Fig. 1).
An additional problem is that the majority of microor-
ganisms in the environment are yet to be cultured and this 
is compounded further by the fact that those from marine 
environments are renowned slow growers (Joint et al. 2010). 
In order to address this, DSMZ researchers have been devel-
oping culturing technologies for less tractable microbes. 
Methods under consideration currently include applications 
already demonstrated in the field e.g. iChip technologies 
(Nichols et al. 2010) and the single-dilution  MicroDrop® 
technique (Bruns et al. 2003). Nichols et al. (2010) designed 
an isolation chip (iChip) composed of several hundred, min-
iature diffusion chambers—each inoculated with a single 
environmental cell. They showed that microbial recovery 
in the iChip exceeds many-fold that afforded by standard 
cultivation, and the species thus obtained are of significant 
phylogenetic novelty. The method allows access to a large 
and diverse array of previously inaccessible microorganisms 
and is well suited for both fundamental and applied research. 
(e.g. Sherpa et  al. 2015). As such, the iChip is a high-
throughput platform for parallel cultivation and isolation of 
previously uncultivated microbial species from a variety of 
environments. Using a microdispenser system, Bruns et al. 
(2003) developed a high-throughput innovative technique for 
the isolation of bacteria in liquid. The  MicroDrop® micro-
dispenser system enables the dispensing of highly reproduci-
ble volumes (0.5 µl to 2.5 ml) in microtiter plates in less than 
1 min per plate allowing the generation of large numbers of 
bacterial enrichments for downstream cultivation and analy-
sis. Using this technique Gich et al. (2005) obtained 570 bac-
terial cultures from which the majority was closely related to 
previously uncultured bacteria. It is necessary to bridge the 
gap between compound identification and compound chemi-
cal characterisation and, ultimately, to gain access to the 
most appropriate methodologies and technologies. Current 
“state of the art” approaches utilise High Resolution Mass 
Spectrometry (MS) and database comparison, coupled with 
genome analysis. Cloning and heterologous expression has 
potential but needs considerable further work. Bouslimani 
et al. (2014) described technologies in mass spectrometry 
of natural products. A key strength being that very small 
quantities of sample are required allowing much structural 
information to be gained from a single mass spectrum. This 
approach is particularly relevant with the slow-growing 
marine organisms and shows why such methods are being 
used to generate information on the selected test strains in 
EMBRIC’s component laboratories currently. Mass spec-
trometry structural analysis workflows are emerging that 
allows faster de-replication and structural elucidation of 
metabolites, facilitating the screening of new biologically 
active compounds.
EMBRIC microbial product discovery 
pipeline output
To date, the work undertaken has involved the strategic iso-
lation of biotechnologically useful microbes using a DSMZ 
biofilm method (Gich et al. 2012) and selection of the most 
promising microbes for extract analysis. DSMZ collected 
samples of sea water, sediment and sponges from the Pacific 
Ocean and from over 900 samples isolated, found 248 spe-
cies considered rare and difficult to grow. These included 
strains from the phyla Actinobacteria, Bacteroidetes, Proteo-
bacteria and Rhodothermaeota. Two new species of Arco-
bacter have been found and there may be more new taxa to 
be reported, as characterisation is ongoing. The partners at 
the University of St Andrews have cloned a large number of 
gene clusters and used promoter refactoring in attempts to 
awaken “sleeping clusters”. As a result, they detected novel 
metabolites demonstrated through the Global Natural Prod-
ucts Social Molecular Networking (GNPS) web-platform.
Helmholtz-Zentrum für Infektionsforschung (HZI) have 
received 156 extracts from DSMZ in total comprising pel-
lets, supernatant and resin extracts of 25 strains which have 
been analysed. The analysis of the LC–MS/MS measure-
ments revealed a total of 557 features detected in at least 
one of four strains; the number of features was reduced to 
312 after discarding features that were found also in the 
control sample (KM14 growth medium). In-house library 
Combining Parallel, Complementary Streams to Speed Discovery
Genomics Metabolomics
Promising strains (from mBRCs) Extracts of strains (from mBRCs)
Genome Sequencing and Reading LC-MSMS and Bioactivity Profiling
Candidate metabolites and clusters identified
Cosmid Library generation, Heterologous Expression
Structural characterization
Compound assessment
Fig. 1  Combining parallel, complementary streams to speed discov-
ery from marine resources
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matching identified 13 of the 312 metabolites found. 
Tyramine and Adenine are the metabolites found in each 
strain with the highest intensity; Glycocholate is present in 
three strains with very high intensity; 2-Deoxyadenosine 
is found with the highest intensity in one strain being pre-
sent only in traces in the other strains (very low intensity); 
see deliverables on EMBRIC website https ://www.embri 
c.eu/deliv erabl es specifically: D6.1 EMBRIC showcases: 
prototype pipelines from the microorganism to product 
discovery (Revised 2019) at https ://www.embri c.eu/sites 
/defau lt/files /deliv erabl es/EMBRI C%20Del ivera ble%20
D6.1b.pdf. Further analysis of the more recently received 
strains is ongoing. An overview of the routes to discovery 
within the EMBRIC project are shown in Fig. 2. Extensive 
analysis of over 150 cell pellet extracts selected from the 
248 strains was carried out via a combination of MS/MS 
in-house library matching and manual dereplication (using 
commercial and online opensource databases) allowed the 
team to assign between 10 and 25% of the detected fea-
tures to known metabolites.
There were a number of outputs of significance from the 
microbial prototype pipeline:
• Flow cytometry and biofilm technologies were used for 
selection of marine organisms in samples that had great-
est potential as candidates for biomass production;
• Combined cosmid and BAC library heterologous expres-
sion approach developed;
• Genome informed use of isotopes to track new metabo-
lites;
• USTAN generated cosmid libraries for a series of more 
tractable and sequenced test strains. Biosynthetic gene 
cluster analysis prioritized nine clusters according to 
novelty. Cosmids containing them were taken into strains 
of Streptomyces coelicolor and Streptomyces lividans for 
heterologous expression. Fermentation broth extracts 
revealed heterologously produced metabolites;
• Larger biosynthetic gene clusters were accessed via a 
complementary BAC library approach, removing the 
need for cluster stitching prior to heterologous expres-
sion;
• Original bottlenecks in getting sufficient DNA for analy-
sis were overcome:
• Expression level: addressed by introduction of pro-
moters, utilization of different heterologous hosts, 
and utilization of small molecule elicitors;
• Metabolite de-replication and assignment: addressed 
with cluster analysis of LC–MS/MS data aiding the 
identification of series of closely related compounds;
• Cyclic peptides difficult to characterize: new 
approaches explored by pre-incubation with an 
enzyme;
• HZI have optimized analysis for different metabolite 
classes: e.g. short-chain fatty acids to larger polar and 
nonpolar compounds of primary and secondary metabo-
lism. Lessons learned from the metabolome analysis of 
microalgae in EMBRIC work package 7 (https ://www.
embri c.eu/WP) accelerated their application to the bac-
teria;
• Use of metabolite clustering analysis with a tool made 
available as an R package to assist in the identification 
of novel suites of compounds;
• Use of molecular networking tool from GNPS combined 
with manual dereplication and matching with in-house 
library allowed the faster and more efficient annotation 
of known metabolites. The visualization of the chemi-
cal space at the molecular level gave insights on struc-
tural relationship between chemical entities in the whole 
data set, pointing towards potential novel compounds 
(unknown metabolites);
Raw data and detailed results are to be found on the 
EMBRIC web site under work package 6 deliverables (https 
://www.embri c.eu/deliv erabl es).
Discussion
The coordinated activities of the EMBRIC project has dem-
onstrated that workflows across different ESFRI research 
infrastructures can improve our ability to isolate rare organ-
isms and access their metabolites. The EMBRIC project 
examined the completeness of the necessary workflows for 
key types of marine bioproducts and identified some crucial 
bottlenecks that currently present obstacles to the exploi-
tation of this vast resource. Where possible, strategies to 
overcome the gaps and problems identified in ways that may 
benefit the user community have been determined.
When seeking active molecules for use as an effective 
product, the first step is to identify where the potential solu-
tion might be. Are there already organisms, derivatives or 
even purified compounds that are available (i.e. de-repli-
cation) and how might more be discovered in the marine 
environment? This first step, therefore, may be considered 
to be identifying the potential. Twenty collections registered 
with the World Data Centre for Microorganisms (WDCM) 
hold microorganisms sourced from the marine environ-
ment; amongst them, they house over 334,000 strains. Even 
within the EMBRIC partners, there are collections that are 
not listed on the WDCM; additionally, there are many organ-
isms held by scientists in non-registered collections around 
the world that are not visible to the researcher. The rest of 
the 700 + collections in the WDCM hold over two million 
strains of microorganism, many of which may well originate 
from the marine environment but there is no single place 
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Sourcing organisms
Cultivation and biomass production
Determination of organism potential
Extract production and exploration
Rapid identification of new compounds ensuring mitigation 
against wasted resource on compound rediscovery
Purification of characterised compounds
Protection of investment and future use
Figure 2. Overview of routes to discovery
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Methods
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HZI
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OECD 
(2007); ISO 
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EU-OPEN-
SCREEN 
and MIRRI
IPR; Nagoya 
Protocol 
Fig. 2  Overview of routes to discovery
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where all catalogues can be searched and these strains easily 
revealed. At present, each single collection catalogue would 
need to be searched and only 85 collections (holding a total 
of 356,889 strains) are included in the Global Catalogue of 
Microorganisms (GCM), with only minimal data made avail-
able (https ://gcm.wfcc.info/). A concerted effort, therefore, 
is needed to make these strains more readily accessible: a 
task that can be undertaken by the MIRRI and EMBRIC 
consortia.
When the species coverage is examined it is very easy 
to see that there are large gaps between what is known and 
what is available. There are also estimates that less than 1% 
of the microorganisms that are in the environment have been 
discovered, to date. Thus, the question remains: how can this 
vast resource be tapped? Targeting the organisms and estab-
lishing sampling regimes for the chemistry that is needed, is 
not straightforward. New approaches such as “culturomics” 
are being harnessed; this entails the exhaustive application 
of culture media and growth conditions for the maximum 
recovery of cultivable microorganisms from a biological 
sample (Lagier et al. 2012). It may also be possible to add 
to the traditional methods of “baiting” environments with 
substrates to select specific potential based on chemistry or 
utilising molecular tools or probes and cloning genes. The 
danger of simply employing normal isolation techniques 
to extract and identify the organisms and to get them into 
axenic mono-culture is that the faster growing and/or more 
common organisms will be isolated repeatedly whilst com-
pletely missing the slow-growing or yet-to-be-cultured ones.
Genomic DNA analysis using next generation sequenc-
ing approaches to examine total sample DNA for the yet 
uncultured is notable way forward but accessing the relevant 
expertise and facilities for this is not always obvious. Char-
acterisation technologies, data analysis and applications are 
available and have been identified through this process. The 
key function of the research infrastructures is to give access 
to the resources needed for a researcher to make discov-
eries: e.g. the EMBRIC web tool. ELIXIR, a distributed 
infrastructure for life-science information: https ://www.
elixi r-europ e.org/tools tools offer different ways to find and 
analyse data to enable such compounds to be identified. 
The remaining elements in discovery pipelines, scaling-up, 
extraction, purification and delivery of chemically defined 
compounds are also elements that have been designed for 
some specific cases. EU-OPENSCREEN (https ://www.eu-
opens creen .eu/) in particular has pulled together much of 
the best practice for chemical screening, and offers long-
standing expertise regarding the setup and implementation 
of chemical screens and subsequent hit-to-lead optimiza-
tion. EU-OPENSCREEN works closely with collaborating 
chemists and biologists and provides support throughout the 
entire screening workflow–from the initial idea to the opti-
mized hit. In the context of EMBRIC, newly isolated marine 
compounds can be tested against a variety of biological 
assays using EU-OPENSCREEN in order to obtain bioactiv-
ity profiles of newly isolated compounds (e.g., antimicrobial 
or antiproliferative activities). Moreover, compounds will 
be transferred into the EU-OPENSCREEN comprehensive 
compound library, thus increasing European visibility. All 
of these aspects are organised in such a way that no loss of 
intellectual property occurs.
A fundamental difficulty in assisting bioindustry to access 
the most appropriate targets is getting specific information 
from companies to enable delivery of their needs. To date, 
resource centres and service providers have tried to second-
guess what a company needs, or wants, as many companies 
are reluctant to let others know what they are working on. 
Enabling companies to access and utilise information in 
open databases anonymously misses potential and lessens 
the opportunity to get the collections and their networks to 
make more targets available. Appropriate business models 
with non-disclosure agreements are needed and a common 
agreement enabled for infrastructure partners to allow others 
to act on their behalf.
By pooling expertise, a critical mass can be focused on 
specific user problems, such as, the development of dedi-
cated isolation protocols (e.g. selective media to access the 
microorganisms that cannot yet be cultivated). In terms of 
the bottlenecks associated with specific active molecules, 
gaps between the identification and chemical characteriza-
tion of compounds can be addressed and appropriate bio-
logical assay technology to comprehensively test for bioac-
tivities is available already. Routes from crude extract assay 
hits to identifying and purifying bioactive compounds are 
facilitated across the partner research infrastructures. This 
may be done through access to the most appropriate meth-
odologies and technologies: e.g. common tools and soft-
ware. By accessing the research infrastructures, the loss of 
resources and time, by rediscovery of known and already 
patented compounds, can be avoided (i.e. de-replication). 
Additionally, this approach ensures compliance with regula-
tions, ensuring that permissions to collect are secured where 
needed and legal obligations are met. Experts in technol-
ogy transfer offices across the research infrastructures can 
also help with expertise or simple information on routes to 
market, licensing, product marketing and even production in 
some cases. Above all, research infrastructures must ensure 
that, in creating such platforms and gateways to technologies 
and collaborations, they strive for high quality. Information 
should be collated and incorporated into a web-based tool 
that helps users negotiate the pipeline through the RI facili-
ties in a manner tailored to user needs. In other words, they 
must provide the operational tools that meet community best 
practice with appropriate quality checks and accreditation.
The work of the European Research Infrastructure clus-
ters will continue to evolve through reaction to user needs in 
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order to serve the European Research Area better. Research-
ers are encouraged to use the resources, expertise and facili-
ties available from the European Research Infrastructures 
(https ://www.esfri .eu/roadm ap-2016). In closing, therefore, 
we note the scale of the task facing stakeholders in the blue 
bio-economy and commend the multi-partner, international 
approach encompassed in EMBRIC, as a potential toolkit for 
enabling the use of the largely untapped marine microbial 
ecosystem as a source of novel bioactives in a sustainable 
and responsible manner.
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